Company intelligence
Kiin Bio
Innovate Health
Biotechnology Research
London, GB
10 employees
Founded 2024
4 public signals
About Kiin Bio
Our mission is to bridge AI and Life Sciences. The next breakthrough in drug discovery is a team of Virtual Scientists that designs, runs and interprets complex experiments by intelligently using the right software and data. Kiin Bio is bringing this vision to life with KiinOS. Follow us and subscribe to our newsletter (https://newsletter.kiin.bio/) for actionable intelligence, strategic insights, and unparalleled expertise in AI-driven solutions for the life science sector!
Verified activity
Signals from Kiin Bio
4 published signals
Capital & Finance
Kiin Bio spoke with the founders of sci2sci, who closed a €1.2M pre-seed round co-led by Heliad and IBB Ventures.
Reported by Kiin Bio
Legal & Regulatory
Kiin Bio broke down how Merck spent USD 1 billion developing a subcutaneous Keytruda and why the next patent cliff won't break down.
Reported by Kiin Bio
Research & Knowledge
Kiin Bio published a full breakdown of the 2026-2030 patent cliff for its latest primer.
Reported by Kiin Bio
Research & Knowledge
Kiin Bio published a deep-dive piece on the 2026-2030 patent cliff, breaking down year-by-year exposure, subcutaneous reformulation play, and the GLP-1 cliff.
Reported by Kiin Bio